Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy

Moschovas, Marcio Covas; Chew, Christopher; Bhat, Seetharam; Sandri, Marco; Rogers, Travis; Dell’Oglio, Paolo; Roof, Shannon; Reddy, Sunil; Sighinolfi, Maria Chiara; Patel, Vipul

doi:10.1016/j.euf.2021.03.015

Cited by 21 publications

(18 citation statements)

References 21 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We believe this question will become increasingly relevant to the care of men with PCa. The Oncotype DX Genomic Prostate Score (GPS) assay uses biopsy samples to provide a score ranging from 0 to 100 for men with PCa, to predict the probability of adverse pathology at RP, biochemical recurrence at 3 years and metastasis and PCa-related death at 10 years [135][136][137][138]. In their study including 296 men with a total of 319 prostate biopsies, Greenland et al [133] showed that among different Gleason pattern 4 tumours, the IDC-P/CC pattern was associated with the highest increase in the GPS, with a mean GPS of 42.…”

Section: Commercial Classification Assaysmentioning

confidence: 99%

Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait

Pantazopoulos

Diop

Grosset

et al. 2022

Cancers

View full text Add to dashboard Cite

Intraductal carcinoma of the prostate (IDC-P) is one of the most aggressive types of prostate cancer (PCa). IDC-P is identified in approximately 20% of PCa patients and is associated with recurrence, metastasis, and PCa-specific death. The main feature of this histological variant is the colonization of benign glands by PCa cells. Although IDC-P is a well-recognized independent parameter for metastasis, mechanisms by which IDC-P cells can spread and colonize other tissues are not fully known. In this review, we discuss the molecular portraits of IDC-P determined by immunohistochemistry and genomic approaches and highlight the areas in which more research is needed.

show abstract

Section: Commercial Classification Assaysmentioning

confidence: 99%

Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait

Pantazopoulos

Diop

Grosset

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Multivariate analysis assessing the odds ratio per 20-points change in Oncotype DX genomic score showed that GPS is an independent predictor of adverse pathological features after RP, and specifically for EPE and SVI. At ROC analysis, GPS score did not increase the area under the curve (AUC) of PCSM [38].…”

Section: Oncotype DX Role In Clinical Practicementioning

confidence: 92%

Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer

Ingrosso

Alì

Marani

et al. 2022

JPM

View full text Add to dashboard Cite

In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. These tools although essential in daily clinical practice for the management of such a heterogeneous disease, which can be cured with a wide spectrum of treatment strategies (i.e., active surveillance, RP and radiation therapy), do not allow the precise distinction of an indolent instead of an aggressive disease. In recent years, several prognostic biomarkers have been tested, combined with the currently available clinicopathologic prognostic tools, in order to improve the decision-making process. In the following article, we reviewed the literature of the last 10 years and gave an overview report on commercially available tissue-based biomarkers and more specifically on mRNA-based gene expression classifiers. To date, these genomic tests have been widely investigated, demonstrating rigorous quality criteria including reproducibility, linearity, analytical accuracy, precision, and a positive impact in the clinical decision-making process. Albeit data published in literature, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence.

show abstract

“…Until now there are three (Decipher, Oncotype DX, and Prolaris) broadly discussed assays in management decision making among post-prostatectomy patients [34]. The Oncotype DX assay is a molecular test evaluating 17 genes and is expressed by Genomic Prostate Score (GPS) (scale from 0 to 100) and provide prognostic results about clinicopathological features of PCa (higher score indicate more aggressive disease) Moschovas and co-workers demonstrate on the group of 749 patients that Oncotype DX assay score correlate with PCa pathology after RP and was an independent predictor of extraprostatic extension (odds ratio [OR] 1.8, 95% confidence interval [CI] 1.4-2.3) and seminal vesicle invasion (OR 2.1, 95% CI 1.3-3.4) [35]. It is also shown that GPS positively correlates with PCa metastasis, PCa-specific death and biochemical recurrence [36].…”

Section: Genomic and Proteomic Methodsmentioning

confidence: 99%

Patients with Positive Lymph Nodes after Radical Prostatectomy with Pelvic Lymphadenectomy – Do We Know the Proper Way of Management?

Małkiewicz¹,

Knura²,

Łątkowska³

et al. 2022

Preprint

View full text Add to dashboard Cite

Lymph node invasion in prostate cancer is a significant prognostic factor indicating worse prognosis. While it affects significantly both survival rates and recurrence, proper management remains a heated issue. Thorough evaluation of risk factors associated with nodal involvement, such as lymph node density or extracapsular extension, is crucial to establish potential expansion of the disease and to substratify patients clinically. There are multiple strategies that may be taken into consideration for patients with positive lymph nodes. Nowadays therapeutic methods are generally based on observation, radiotherapy, and androgen deprivation therapy. However current guidelines are incoherent in terms of indication of the most effective management approach. Future management strategies will be expected to reach for novel diagnostic tools and therapies, such as photodynamic therapy or diagnostic imaging with prostate specific membrane antigen. Nevertheless, this heterogeneous group of men remains a vast therapeutic concern, and both clarification of the guidelines and optimal substratification of patients is required.

show abstract

Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy

Cited by 21 publications

References 21 publications

Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait

Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait

Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer

Patients with Positive Lymph Nodes after Radical Prostatectomy with Pelvic Lymphadenectomy – Do We Know the Proper Way of Management?

Contact Info

Product

Resources

About